聖諾醫藥-B(02257.HK):主要候選產品治療皮膚癌臨床獲積極中期數據
聖諾醫藥-B(02257.HK)公布,正在進行的STP705用於治療原位鱗狀細胞皮膚癌(isSCC)的Ⅱb期第一階段的中期臨床數據。中期報告顯示,在32名受試者中,25名受試者接受STP705治療後實現了較高的組織學清除率(78%)。
公司指,STP705是其主要候選產品,已獲得美國食品藥品監督管理局(FDA)和中國國家藥品監督管理局
(NMPA)的多項IND批准,包括用於治療膽管癌、非黑色素瘤皮膚癌和增生性瘢痕。另獲得治療膽管癌和原發性硬化性膽管炎的孤兒藥資格。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.